James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.
Understanding the Role of JAK Inhibitors
A review of topical JAK inhibitor ruxolitinib.
Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.
Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5